medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 6

<< Back Next >>

Ann Hepatol 2013; 12 (6)

Liver retransplantation in adults: a 20-year experience of one center in southern Brazil

Costabeber AM, Granzotto M, de Medeiros FJA, Marroni CA, Zanotelli ML, Cantisani G, Lionço L, Musskopf MI, Brandão A

Language: English
References: 46
Page: 942-951
PDF size: 130.47 Kb.


ABSTRACT

Introduction. Liver retransplantation (LReTx) is the therapeutic option for hepatic graft failure. Survival after LReTx is poorer than after primary liver transplantation. Given the organ shortage, it is essential to optimize the use of this resource. Objective. To evaluate rates, indications and patient survival after LReTx and identify factors associated with mortality following LReTx. Material and methods. We conducted a retrospective cohort study of all adults undergoing LReTx based on registry data from the Liver Transplantation Group (Complexo Hospitalar Santa Casa de Porto Alegre), southern Brazil. Results. Between June 16, 1991 and July 19, 2011, 824 patients underwent 866 liver transplants. Forty-two procedures corresponded to LReTx (4.8% of all liver transplants performed). Thirty-eight patients who underwent a single LReTx procedure were included in this study. The leading indication for LReTx was hepatic artery thrombosis (HAT) (31.6%), followed by primary nonfunction (PNF) (18.4%). The main indication for early LReTx was PNF (58.3%) and for late LReTx was HAT (38.5%). During the follow-up period, 26 patients (68.4%) died after LReTx. Patient survival at 1 and 3 years after LReTx was 44.7% and 44.7%, respectively. Patients infected with hepatitis C virus, serum albumin ‹ 2.5 g/dL and receiving mechanical ventilation immediately before LReTx had a significantly lower survival rate than the other patients. Conclusion. Considering the increased mortality when the graft loss is delayed, it is necessary to define the minimum acceptable results to indicate LReTx and identify the patients who would most benefit from this treatment.


REFERENCES

  1. Maggi U, Consonni D, Bertoli P, Caccamo L, Reggiani P, Melada E, Rossi G. A risk score and a flowchart for liver retransplantation. Transplant Proc 2008; 40: 1956-60.

  2. Meneu Diaz JC, Moreno Gonzalez E, Vicente E, García I, Nuño J, Loinaz C, Quijano Y, et al. Early mortality in liver retransplantation: a multivariate analysis of risk factors. Transplant Proc 2002; 34: 301-2.

  3. Doyle HR, Morelli F, McMichael J, Doria C, Aldrighetti L, Starzl TE, Marino IR. Hepatic Retransplantation-an analysis of risk factors associated with outcome. Transplantation 1996; 61: 1499-505.

  4. European Liver Transplant Registry (ELTR). Mortality and retransplantation. Available from: http://www.eltr.org/ spip.php?article188 [Accessed on July 07, 2012].

  5. Magee JC, Barr ML, Basadonna GP, Johnson MR, Mahadevan S, McBride MA, Schaubel DE, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 2007; 7: 1424-33.

  6. Reed A, Howard RJ, Fujita S, Foley DP, Langham MR, Schold JD, Nelson D, et al. Liver retransplantation: a single-center outcome and financial analysis. Transplant Proc 2005; 37: 1161-3.

  7. Markmann JF, Markowitz JS, Yersiz H, Morrisey M, Farmer DG, Farmer DA, Goss J, et al. Long-term survival after retransplantation of the liver. Ann Surg 1997; 226: 408-20.

  8. Marudanayagam R, Shanmugam V, Sandhu B, Gunson BK, Mirza DF, Mayer D, Buckels J, et al. Liver retransplantation in adults: a single-centre, 25-year experience. HPB 2010; 12: 217-24.

  9. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002; 8: 313-22.

  10. De Carlis L, Slim AO, Giacomoni A, DiBenedetto F, Pirotta V, Lauterio A, Sammartino C, et al. Liver retransplantation: indications and results over a 15-year experience. Transplant Proc 2001; 33: 1411-3.

  11. Rosen HR, Prieto M, Casanovas-Taltavull T, Cuervas-Mons V, Guckelberger O, Muiesan P, Strong RW, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38: 460-9.

  12. Bilbao I, Figueras J, Grande L, Clèries M, Jaurrieta E, Visa J, Margarit C. Risk factors for death following liver retransplantation. Transplant Proc 2003; 35: 1871-3.

  13. Crivellin C, De Martin E, Germani G, Gambato M, Senzolo M, Russo FP, Vitale A, et al. Risk factors in liver retransplantation: a single-center experience. Transplant Proc 2011; 43: 1110-3.

  14. Martí J, Charco R, Ferrer J, Calatayud D, Rimola A, Navasa M, Fondevila C, et al. Optimization of liver grafts in liver retransplantation: a European single-center experience. Surgery 2008; 144: 762-9.

  15. Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, Dodson SF, Marsh W, et al. Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc 2001; 33: 1486-7.

  16. Torres-Quevedo R, Moya-Herraiz A, San Juan F, Rivera J, López-Andujar R, Montalvá E, Pareja E, et al. Indications and results of liver retransplantation: experience with 1181 patients at the University Hospital La Fe. Cir Esp 2010; 87: 356-63.

  17. Alamo JM, Gómez MA, Pareja F, Martínez A, López F, Romero E, Barrera L, et al. Morbidity and mortality in liver retransplantation. Transplant Proc 2006; 38: 2475-7.

  18. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, Ichai P, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002; 236: 713-21.

  19. Linhares MM, Azoulay D, Matos D, Castelo-Filho A, Triviño T, Goldenberg A, Castaing D, et al. Liver retransplantation: a model for determining long-term survival. Transplantation 2006; 81: 1016-21.

  20. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  21. Brandão A, Fuchs SC, Gleisner AL, Marroni C, Zanotelli ML, Cantisani G. Model for the end-stage liver disease and death prediction in a cohort of Brazilian patients on the waiting list for liver transplantation. Clin Transplant 2008; 22: 651-6.

  22. Brazil, Ministry of Health. Department of Health Care. Ordinance No. 1,160 of May 29, 2006. Brasília: Official Gazette No. 103 (May 31, 2006).

  23. Kim HJ, Larson JJ, Lim YS, Kim WR, Pedersen RA, Therneau TM, Rosen CB. Impact of MELD on waitlist outcome of retransplant candidates. Am J Transplant 2010; 10: 2652-7.

  24. Onaca N, Levy MF, Ueno T, Martin AP, Sanchez EQ, Chinnakotla S, Randall HB, et al. An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. Transpl Int 2006; 19: 282-7.

  25. Ravaioli M, Grazi GL, Ercolani G, Cescon M, Varotti G, Del Gaudio M, Vetrone G, et al. Efficacy of MELD score in predicting survival after liver retransplantation. Transplant Proc 2004; 36: 2748-9.

  26. Maggi U, Andorno E, Rossi G, De Carlis L, Cillo U, Bresadola F, Mazzaferro V, et al. Liver retransplantation in adults: the largest multicenter Italian study. PLOS One 2012; 7: 1-7.

  27. Starzl TE, Hakala TR, Shaw BW Jr, Hardesty RL, Rosenthal TJ, Griffith BP, Iwatsuki S, et al. A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet 1984; 158: 223-30.

  28. Starzl TE, Miller C, Broznick B, Makowka L. An improved technique for multiple organ harvesting. Surg Gynecol Obstet 1987; 165: 343-8.

  29. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.

  30. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-26.

  31. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2006 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2007. Available from: http:// www.srtr.org/annual_Reports/default.aspx [Accessed on July 23, 2012].

  32. Ferraz-Neto BH, Zurstrassen MP, Hidalgo R, Rezende MB, Meira-Filho SP, Pandullo FL, Fonseca LE, et al. Results of urgent liver retransplantation in the State of São Paulo, Brazil. Transplant Proc 2006; 38: 1911-2.

  33. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmüller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl 2003; 9: 612-20.

  34. Torres-Quevedo R, Moya-Herraiz A, San Juan F, López-Andujar R, Montalva E, Pareja E, De Juan M, et al. Indications for and results of liver retransplantation. Transplant Proc 2009; 41: 1016-7.

  35. Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant 2009; 9: 746-57.

  36. Gunsar F, Rolando N, Pastacaldi S, Patch D, Raimondo ML, Davidson B, Rolles K, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl 2003; 9: 605-11.

  37. Oh CK, Pelletier SJ, Sawyer RG, Dacus AR, McCullough CS, Pruett TL, Sanfey HA. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 2001; 71: 767-72.

  38. Leithead JA, Smith MR, Materacki LB, Sagar VM, Gunson BK, Bramhall SR, Mutimer DJ, et al. Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation. Liver Transpl 2012; 18: 1353-60.

  39. Burton JR Jr, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis 2006: 10; 407-35.

  40. Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, et al. Early diagnosis of primary nonfunction and indications for reoperation after liver transplantation. Liver Transpl 2010; 16: 172-80.

  41. Uemura T, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, McKenna GJ, Chinnakotla S, et al. Liver retransplantation for primary nonfunction: analysis of a 20-year singlecenter experience. Liver Transpl 2007; 13: 227-33.

  42. Kremers WK, van I Jperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39: 764-9.

  43. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10; 1003-19.

  44. Pfitzmann R, Benscheidt B, Langrehr JM, Schumacher G, Neuhaus R, Neuhaus P. Trends and experience in liver retransplantation over 15 years. Liver Transpl 2007; 13: 248-57.

  45. Brandão A, Fuchs SC, Gleisner AL, Marroni C, Zanotelli ML, Cantisani G; Liver Transplantation Group. MELD and other predictors of survival after liver transplantation. Clin Transplant 2009; 23: 220-7.

  46. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434-40.




2020     |     www.medigraphic.com